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Abstract New phenothiazine derivatives as 10-substituted
dipyridothiazines of the 1,6-diazaphenothiazine structure
were obtained in the cyclization reaction of 3-amino-3′-
nitro-2,2′-dipyridinyl sulﬁde and 3,3′-dinitro-2,2′-dipyr-
idinyl disulﬁde, and in the reaction of 2-chloro-3-ntropyr-
idine with sodium 3-amino-2-pyridinethiolate followed by
various alkylation and arylation reactions. The reaction of
the thiazine ring formation ran via the Smiles rearrange-
ment of the S-N type. As the alkylation reactions could
proceed at the thiazine, azine or both nitrogen atoms, the
product structure elucidation was based on the 2D NMR
(Rotating-frame Overhauser Effect Spectroscopy, Corre-
lated Spectroscopy, Heteronuclear Single Quantum
Coherence, and Heteronuclear Multiple Bond Correlation)
spectra of the N-methylated product. Some 10-substituted
1,6-diazaphenothizines (5, 10, 12, 13) were at least antic-
ancer active against melanoma C-32 and breast cancer
MCF-7 cell lines as a reference drug – cisplatin. The
monoazaphenothiazine drug, prothipendyl, turned out to be
less active than least 6 derivatives of the 1,6-diazaphe-
nothiazine structure.
Keywords Phenothiazines ● Dipyridothiazines ● NMR
structure elucidation ● 2D NMR spectra ● The Smiles
rearrangement ● Anticancer activity
Introduction
Tricyclic phenothiazines (dibenzo-1,4-thiazines) are
important class of heterocycles possessing signiﬁcant bio-
logical activities and interesting chemical features. Classical
10-substituted phenothiazines with the aminoalkyl groups at
the nitrogen atom have been for many years valuable drugs
exhibiting neuroleptic, antihistaminic, antitussive, and
antiemetic activities (Gupta and Kumar, 1988). They are
relatively easy-obtainable, inexpensive, and low toxic, and
they can be valuable source for searching new drugs of
other biological activities. The chemical structure mod-
iﬁcations of these compounds were carried out mainly by
introduction of new substituents at the thiazine nitrogen
atom and substitution of one or two benzene rings with
homoaromatic and heteroaromatic rings. Such modiﬁcations
are expected to change not only potency but also types of
activities. Both classical and modiﬁed phenothiazines are
found to exhibit very promising anticancer, antibacterial,
antifungal, anti-inﬂammatory, and multidrug resistance
reversal activities, summarized recently in the review arti-
cles and chapters in monographs (Motohashi et al., 2000,
2006; Mitchell, 2006; Dasgupta et al., 2008; Aaron et al.,
2009; Sudeshna and Parimal, 2010; Pluta et al., 2011;
Wesołowska, 2011; Jaszczyszyn et al., 2012). They show
also a potential beneﬁt in treatment of Alzheimer’s,
Creutzfeldt-Jakob’s, and AIDS-associated diseases (Mos-
naim et al., 2006; González-Muñoz et al., 2010).
The last type of the modiﬁcation with azine rings lead to
formation of azaphenothiazines. Our strategy for modiﬁcation
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of the phenothiazine structure is based on the introduction of
two pyridine rings instead of the benzene ones to form various
dipyrido[1,4]thiazines. We found new dipyrido[1,4]thiazines
of the 1,8- and 2,7-diazaphenothiazine structures to exhibit
promising anticancer activity against lung cancers HOP-62
and HOP-92, colon cancers COLO 205, HCT-116 and SW-
948, renal cancers RXF393 and A498, and leukemia HL-60
(TB) and L-1210 (Pluta et al., 2010; Morak-Młodawska et al.,
2015). 10H-2,7-diazaphenothiazine shows also immunosup-
pressant, inhibiting both humoral and cellular immune
responses, and antioxidant properties (Zimecki et al., 2009;
Morak-Młodawska et al., 2010).
It is well known that the synthesis of phenothiazine and
azaphenothiazine ring system may proceed via 1,4-thiazine
ring formation with the use of diphenyl sulﬁdes, phenyl
azinyl sulﬁdes or diazinyl sulﬁdes directly in the Ullmann
cyclization or indirectly through the Smiles rearrangement
of the S-N type to diphenylamines, phenylazinylamines,
and diazinylamines followed by cyclization. During the
rearrangement, the phenyl or azinyl part migrates from the
sulfur atom to the nitrogen atom (Pluta et al., 2009; Silberg
et al., 2006). There only two reports of double Smiles
rearrangement during those syntheses (Morak et al., 2002;
Morak-Młodawska et al., 2012).
The synthesis of 10-substituted derivatives from 10H-
diazaphenothiazines by the alkylation of the thiazine
nitrogen atom can be disturbed by alkylation of the azine
nitrogen atom.
For those reasons, the unquestioned elucidation of the
structure of the direct product, NH-azaphenothiazine, and
its N-substituted derivatives is crucial.
In continuation of those studies we have worked out an
efﬁcient synthesis of another type of dipyridothiazines,
10H-1,6-diazaphenothiazine, and the transformation of this
parent compound into 10-substituted derivatives, possessing
alkyl, arylalkyl, heteroaryl and dialkylaminoalkyl, and
imidoalkyl groups. In this work, we discuss the synthesis
and the structure elucidation of the NH- and N-alkyl-1,6-
diazaphenothiazines, and their anticancer activity.
Results and discussion
Chemistry
The possibility of the Smiles rearrangement depends on the
sulﬁde structure and reaction conditions. The most often the
rearrangement proceeds under basic conditions (sodium
hydroxide in ethanol), rarely under neutral or acidic media. It
is sometimes difﬁcult to state if the rearrangement took place
as the rearranged and non-rearranged products can have the
same or similar structure. In the last case, the structure dif-
ference is in the location of a substituent or a nitrogen atom
(in the azaphenothiazine structure) (Pluta et al., 2009).
In our case, 3-amino-3′-nitro-2,2′-dipyridinyl sulﬁde 4
(obtained from 2-chloro-3-nitropyridine 1 and sodium 3-
amino-2-pyridinethiolate 3 in ethanol) heated in reﬂuxing
N,N-dimethylformamide (DMF) solution did not undergo
cyclization to symmetrical 10H-4,6-diazaphenothiazine 5
(giving only three aromatic proton signals in the 1H NMR
spectrum) but to 10H-1,6-diazaphenothiazine 7 in 90%
yield. It means that the synthesis proceeded through the
Smiles rearrangement to dipyridinylamine 6 (which was not
isolated, Scheme 1). We found 3,3′-dinitro-2,2′-dipyridinyl
disulﬁde 2 (obtained from compound 1 to give compound 3)
to be quite a good substrate to form 1,6-diazaphenothiazine 7
(in 72% yield) in boiling DMF in the presence of sodium
hydroxide. This is very useful synthesis because disulﬁde can
be obtained from commercially available 2-chloro-3-nitro-
pyridine 1 in 89% yield. The same phenothiazine product
was obtained directly (in 64% yield) from pyridines 1 and 3
in boiling DMF. It is not the ﬁrst synthesis of 10H-1,6-
Scheme 1 Synthesis of 10H-
1,6-diazaphenothiazine 7
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diazaphenothiazine 7 as Rodig and coworkers obtained
compound 7 in low yield (43%) in cyclization of 3-acet-
ylamino-3′-nitro-2,2′-dipyridinyl sulﬁde in ethanolic solution
of potassium hydroxide and in very good yield (92%) in
cyclization of dipyridinylamine 6 in DMSO-ethanol solution
of potassium hydroxide. In both cases the reactions substrates
were obtained in two steps using 2-chloro-3-nitropyridine 1
(Rodig et al., 1966).
The next step was transformation of compound 7 into
N-substituted derivatives mainly by alkylation. Although
the alkylation of phenothiazines proceeds mainly at the
thiazine nitrogen atom, there are a few reports on the
alkylation of azaphenothiazines at the azine nitrogen atom
giving azaphenothiazinium salts and neutral N-alkylaza-
phenothiazines (Clarke et al., 1961; Werle et al., 1962;
Pappalardo et al., 1973; Carter and Cheeseman, 1977; Saari
et al., 1983). We studied the reaction of compound 7 with
methyl iodide in dry DMF in the presence of sodium
hydride. The methylated product possessed only one methyl
group (observed in the 1H NMR spectrum) without the
ammonium function what could point at the structure 8. To
exclude alternative neutral N-methylazaphenothiazine
structure i.e. 1-methyl-1,6-diazaphenothiazine 8A, we
recorded 2D NMR (Rotating-frame Overhauser Effect
Spectroscopy (ROESY), Correlated Spectroscopy (COSY),
Heteronuclear Single Quantum Coherence (HSQC), and
Heteronuclear Multiple Bond Correlation (HMBC)) spectra
of the N-methyl product. The ROESY experiment with
irradiation of the methyl protons at 3.40 ppm showed the
proximity of the methyl group to the proton at 6.98 ppm
(γ-pyridinyl proton) and pointed at the structure 8. Only
spatial 1H–1H connectivity with a proton at about 8 ppm (α-
pyridinyl proton) could point at the structure 8A. The full
proton signal assignment was achieved by study of other
proton spatial proximity (ROESY) and 1H—1H con-
nectivities (COSY). The signal at 6.98 ppm was assigned as
H-9 proton. The conﬁrmation of the proton assignment
came from the 13C NMR spectrum which was solved by the
use of HSQC and HMBC spectra indicating the 13C–1H
relationship. The HSQC spectrum showed which proton
was bonded to the carbon atom (the C–H relationship
through one bond, 1JC,H connectivity) and the HMBC
spectrum indicated the C–H relationship through three
(predominantly), two and four (exceptionally) bonds (3JC,H,
2JC,H and
4JC,H connectivities). Selected spatial proton-
proton proximity, proton-proton and proton-carbon con-
nectivities for compound 8 were shown in Scheme 2. The
all 1H–1H and 1H–13C connectivities were included in
Table 1. The resulted product was identiﬁed as 10-
methyldipyrido[2,3-b;2′,3′-e][1,4]thiazine 8. The 1H and
13C NMR spectra of the rest compounds were solved using
the HSQC and HMBC experiments.
The parent product 7 was transformed into new deriva-
tives possessing the allyl (9), propargyl (10), benzyl (11),
nitropyridinyl (12), phthalimidopropyl (17) and the dia-
lkylaminoethyl (13–16, with cyclic and non-cyclic amine
group) substituents in the reactions of appropriate dialky-
laminoethyl halides in the presence of base (NaH, NaOH,
t-BuOK) in neutral solvents. The propargyl derivative 10
was converted into the dialkylaminobutynyl derivatives 18
Scheme 2 The 2D NMR
experiments for compound 8:
ROESY, COSY, HSQC, and
HMBC (selected connectivities)
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and 19 (with the triple bond) via the Mannich reaction with
formaldehyde and secondary amine (non-cyclic and cyclic)
in the presence of copper(I) chloride in dioxane (Scheme 3).
Anticancer activity
The anticancer activity of 1,6-diazaphenothiazines 7–19 was
investigated in vitro using cultured glioblastoma SNB-19,
melanoma C-32 and breast cancer MCF-7 cell lines. Normal
human ﬁbroblast (HFF-1) cell line was used as a control and
cisplatin as a reference drug. To compare the inﬂuence of
the nitrogen atoms in the azaphenothiazine system on the
anticancer activity, the classical monoazaphenothiazine
drug, prothipendyl (10-dimethylaminopropyl-1-azaphe-
nothiazine), was also tested. The tested compounds exhib-
ited different activities against the cell lines. The MCF-7
cell line was found as very sensitive for most compounds.
Eight derivatives exhibited good anticancer activity with
IC50 o 10 μg/mL (Table 2). The most active (IC50 o 5 μg/
mL) were compounds 7, 10 and 12 with the hydrogen atom,
and the propargyl and nitropyridinyl groups. Those
compounds were more active than cisplatin. Compound 19
(with the methylpiperazinylbutynyl group) was as active as
cisplatin and compounds 13, and 17 (with the diethylami-
noethyl and phthalimidopropyl groups) were slightly less
active.
The parent compound 7 and derivative 13 (with the
diethylaminoethyl group) were as active as cisplatin against
melanoma C-32 cell line. The SNB-19 cell line was the
most resistant for the tested compounds. The most active
derivative 9 (with the allyl group) exhibited IC50 close to
20 μg/mL.
Compounds 11, 15 and 18 (with the benzyl, piper-
idinylethyl and diethylaminobutynyl groups) were com-
pletely inactive against all cell lines with IC504 50 μg/mL.
Prothipendyl, containing only one pyridine ring, was
moderately active only against the MCF-7 cell line but
about 5-6 times less active than the most active diazaphe-
nothiazines. It worth noting that the most active compounds
7, 12 and 13 (together with six other compounds) were non-
toxic against normal ﬁbroblasts (HFF-1) with the IC504
50 μg/mL whereas cisplatin turned out to be toxic.
Table 1 The 1H and 13C NMR
assignment, and full proton–
proton and proton–carbon
connectivities (ROESY, COZY,




ROESY COSY 13C NMR δ
(ppm)
HSQC HMBC
CH3 3.40 3.40–6.98 — CH3 32.84 3.40–32.84 3.40–120.31/139.73/
153.49
H3 6.81 6.98–3.40/7.05 6.98–7.05 C4a 116.62 6.81–118.19 6.81–116.62/134.66/
145.29
H9 6.98 6.81–7.31 6.81–7.31/8.04 C3 118.19 6.98–122.11 6.98–142.62/144.76
H8 7.05 7.05–6.98 7.05–7.31/6.98 C9 120.31 7.05–122.11 7.05–139.73/142.62
H4 7.31 7.31–6.81 7.31–6.81 C8 122.11 7.31–134.66 7.31–145.29/153.49
H7 8.02 — 8.02–7.05 C4 134.66 8.02–142.62 8.02–122.11/144.76/
120.31






Scheme 3 Synthesis of 10-substituted 1,6-diazaphenothiazines
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Conclusion
We report here synthesis of new 10-substituted 1,6-diaza-
phenothiazines. Parent compound, 10H-1,6-diazaphe-
nothiazine 7, was obtained in three ways from appropriate
dipyridinyl sulﬁde and disulﬁde, and a pair of 2,3-dis-
ubstituted pyridines. The thiazine ring formation ran via the
Smiles rearrangement of the S-N type. The parent com-
pound was transformed into 10-subtituted derivatives with
the alkyl, heteroaryl, dialkylaminoalkyl, dialkylaminoalk-
ynyl and imidoalkyl groups in the alkylation and hetero-
arylation reactions. As the alkylation reactions could
proceed at the thiazine, azine or both nitrogen atoms, the
product structure elucidation was based on the 2D NMR
(ROESY, COSY, HSQC, and HMBC) spectra of the N-
methylated product. Some 1,6-diazaphenothiazines (7, 10,
12, 13) were at least anticancer active against melanoma C-32
and breast cancer MCF-7 cell lines as a reference drug –
cisplatin. Monoazaphenothiazine drug, prothipendyl, turned
out to be less active than at least six derivatives of 1,6-
diazaphenothiazines against all three cancer cell lines.
Experimental
Chemistry
Melting points were determined in open capillary tubes on a
Boetius melting point apparatus and are uncorrected. The
1H, 13C NMR, COSY, NOESY, HSQC, HMBC spectra
were recorded on a Bruker AscendTM 600 spectrometer at
600MHz in deuteriochloroform with tetramethylsilane as
the internal standard. The 13C NMR spectra were recorded
at 150MHz. Electron impact mass spectra (EI MS) and fast
atom bombardment mass spectra (FAB MS, in glycerol)
were run on a Finnigan MAT 95 spectrometer at 70 eV. The
thin layer chromatography was performed on silica gel 60
F254 (Merck 1.05735) with CHCl3–EtOH (5:1 and 10:1 v/v)
and on aluminum oxide 60 F254 neutral (type E) (Merck
1.05581) with CHCl3–EtOH (10:1 v/v) as eluents.
Synthesis of 3,3′-dinitro-2,2′-dipyridinyl disulﬁde (2)
A solution of 2-chloro-3-nitropyridine (1) (158 mg, 1 mmol)
and thiourea (152 mg, 2 mmol) in ethanol (10 mL) was
reﬂuxed for 3 h. After cooling the resulting crystals were
ﬁltered off, washed with water and air dried to give 3,3′-
dinitro-2,2′-dipyridinyl disulﬁde (2) as orange needles (140
mg, 89 %) m.p. 249–250 °C. 1H NMR (CDCl3) δ: 7.32 (dd,
J= 7.8 Hz, J= 4.2 Hz, 2H, H5, H5′), 8.57 (dd, J= 7.8 Hz, J
= 1.2 Hz, 2H, H4, H4′), 8.61 (dd, J= 4.2 Hz, J= 1.2 Hz, 2H,
H6, H6′).
13C NMR (CDCl3) δ: 120.82 (2CH, C5, C5′),
133.80 (2CH, C4, C4′), 146.71 (2CH, C3, C3′), 153.54
(2CH, C6, C6′), 161.02 (2C, C2, C2′, CS). EI MS m/z: 310
(M, 5), 156 (M+1-NO2C5H3N, 25) 92 (100). Anal. calcd.
for: C10H6N4O4S2, C 38.71; H 1.95, N 18.06. Found: C
38.51, H 1.63, N 17.99.
Synthesis of sodium 3-amino-2-pyridinethiolate (3)
To a solution of 3,3′-dinitro-2,2′-dipyridinyl disulﬁde (2)
(310 mg, 1 mmol) in absolute ethanol (30 mL) two tablets of
NaBH4 (10 mmol) were added carefully and the solution
was reﬂuxed for 2 h. After cooling the solvent was removed
and evaporated in vacuo. The dry residue was recrystallized
from ethanol, yielding brown crystals of sodium 3-amino-2-
pyridinethiolate (3) (230 mg, 71%), m.p.4 260 °C. After
acidiﬁcation with 10 % solution of HCl, 3-aminopyridine-2
(1H)-thione was obtained, m.p. 131–132 °C (lit. (Rodig et
al., 1964) 131–132 °C).
Synthesis of 3-amino-3′-nitro-2,2′-dipyridinyl sulﬁde (4)
To a solution of sodium 3-amino-2-pyridinethiolate (3)
(148 mg, 1 mmol) in dry ethanol (10 mL) 2-chloro-3-nitro-
pyridine (1) (158 mg, 1 mmol) was added. The mixture was
stirred at room temperature for 3 h and next the resulting
brown crystals were ﬁltered off, washed with ethanol, air
dried and recrystallized from ethanol, yielding 3-amino-3′-
nitro-2,2′-dipyridinyl sulﬁde (4) as yellow needles (220 mg,
89 %), m.p. 166 °C (lit. [27] 167–168 °C)).
1H NMR (CDCl3) δ: 7.12 (m, 1H), 7.24 (m, 1H), 7.49 (m,
1H), 8.13 (broad s, 2H, NH2), 8.23 (m, 1H), 8.53 (m, 1H),
Table 2 The anticancer activity of derivatives of 1,6-
diazaphenothiazines
No. Anticancer activity IC50 (μg/mL)
SNB-19 C-32 MCF-7 HFF-1
7 32.8 7.5 4.8 >50
8 33.3 >50 9.1 >50
9 18.9 44.1 42.3 31.6
10 >50 27.1 3.9 6.1
11 >50 >50 >50 >50
12 28.2 32.0 4.6 >50
13 24.2 6.6 8.2 >50
14 >50 >50 10.7 >50
15 >50 >50 >50 >50
16 31.3 16.3 9.4 10.0
17 >50 >50 8.2 >50
18 >50 >50 >50 >50
19 49.1 35.3 7.5 46.6
Prothipendyl 48.7 >50 23.2 >50
Cisplatin 7.7 7.8 7.4 8.2
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8.64 (m, 1H). 1H NMR (CDCl3) δ: 4.27 (broad s, 2H, NH2),
7.12 (m, 1H, H4), 7.24 (m, 2H, H5, H5′), 8.14 (m, 1H, H4′),
8.55 (m, 2H, H6, H6′).
13C NMR (CDCl3) δ: 119.87 (CH,
C5), 122.56 (CH, C4), 125.80 (CH, C5′), 133.80 (CH, C6),
135.66 (C, C3), 140.79 (CH, C4′), 142.29 (C, C2), 146.81 (C,
C3′), 153.62 (CH, C6′), 156.52 (C, C2′). EI MS m/z: 248 (M,
25), 202 (M+1-NO2 100). Anal. calcd. for: C10H8N4O2S, C
48.38, H 3.25, N 22.57. Found: C 48.42, H 3.39, N 22.51.
Synthesis of 10H-1,6-diazaphenothiazine (7)
From 2-chloro-3-nitropyridine (1) and sodium 3-amino-2-
pyridinethiolate (3) To a solution of sodium 3-amino-4-
pyridinethiolate (3) (148 mg, 1mmol) in dry DMF (10mL) 2-
chloro-3-nitropyridine (1) (158mg, 1 mmol) was added. The
mixture was stirred at room temperature for 1 h and next was
reﬂuxed for 4 h. After cooling the reaction mixture was eva-
porated in vacuo. The dry residue was dissolved in CHCl3
and puriﬁed by column chromatography (aluminum oxide,
CHCl3) to give 10H-1,6-diazaphenothiazine (7) as beige
needles (EtOH) (130mg, 64%), m.p. 191–192 °C (lit. (Rodig
et al., 1966) 223–225 °C). 1H NMR (CDCl3) δ: 6.68 (dd, J
= 7.8 Hz, J= 1.2 Hz, 1H, H9), 6.72 (1H, NH), 6.73 (dd, J=
7.2Hz, J= 4.8 Hz, 1H, H3), 6.88 (dd, J= 7.2 Hz, J= 4.8 Hz,
1H, H8), 7.18 (dd, 1H, J= 7.8Hz, J= 1.2 Hz, H4), 7.81 (dd,
J= 4.8 Hz, J= 1.2Hz, 1H, H7), 7.92 (dd, J= 4.8Hz, J= 1.2
Hz, 1H, H2).
13C NMR (CDCl3) δ: 114.49 (C4a), 118.54 (C3),
120.21 (C9), 122.20 (C8), 134.31 (C4), 136.31 (C9a), 141.37
(C5a), 143.28 (C7), 145.45 (C2), 151.22 (C10a). EI MS m/z:
201 (M, 100). Anal. calcd. for: C10H7N3S, C 59.68, H 3.51, N
20.88. Found: C 59.51, H 3.53, N 20.82.
In cyclization of 3-amino-3′-nitro-2,2′-dipyridinyl sulﬁde (4)
The brown solution of 3-amino-3′-nitro-2,2′-dipyridinyl sul-
ﬁde (4) (124mg, 0.5mmol) in dry DMF (5mL) was reﬂuxed
for 4 h. After cooling the reaction mixture was evaporated in
vacuo. The dry residue was dissolved in CHCl3 and puriﬁed
by column chromatography (aluminum oxide, CHCl3) to give
10H-1,6-diazaphenothiazine (7) (90mg, 90%).
In cyclization of 3,3′-dinitro-2,2′-dipyridinyl disulﬁde (2)
To a solution of 3,3′-dinitro-4,4′-dipyridinyl disulﬁde (2)
(310 mg, 1 mmol) in dry DMF (10 mL) NaOH (120 mg,
3 mmol) was added and reﬂuxed for 48 h. After cooling the
reaction mixture was evaporated in vacuo. The dry residue
was dissolved in CHCl3 and puriﬁed by column chroma-
tography (aluminum oxide, CHCl3) to give 10H-1,6-diaza-
phenothiazine (7) (144 mg, 72 %).
Synthesis of 10-substituted 1,6-diazaphenothiazines 8–12
To a solution of 10H-1,6-diazaphenothiazine (7) (100 mg,
0.5 mmol) in dry DMF (5 mL) NaH (24 mg, 1 mmol, 60 %
NaH in mineral oil was washed out with hexane) was
added. The reaction mixture was stirred at room temperature
for 1 h and then alkyl or heteroaryl halides (methyl iodide,
allyl bromide, benzyl chloride, 4-chloro-3-pyridine, 1.5
mmol) was added and the stirring was continued for 24 h.
The mixture was poured into water (15 mL), extracted with
CHCl3 (3 × 10 mL) and dried using anhydrous Na2SO4. The
obtained product was puriﬁed by column chromatography
(aluminum oxide, CHCl3) to give:
10-Methyl-1,6-diazaphenothiazine (8) (98 mg, 91 %); light
brown needles (EtOH), m.p. 105–106 °C 1H NMR
(CDCl3) δ: 3.40 (s, 3H, CH3), 6.81 (dd, J= 7.2 Hz, J= 4.8
Hz, 1H, H3), 6.98 (d, J= 7.8 Hz, 1H, H9), 7.05 (dd, J= 7.8
Hz, J= 4.8 Hz, 1H, H8), 7.31 (dd, 1H, J= 7.2 Hz, J= 1.2
Hz, H4), 8.02 (dd, J= 4.2 Hz, J= 1.2 Hz, 1H, H7), 8.04 (dd,
J= 4.2 Hz, J= 1.2 Hz, 1H, H2).
13C NMR (CDCl3) δ: 32.84
(NCH3), 116.62 (C4a), 118.19 (C3), 120.31 (C9), 122.11
(C8), 134.66 (C4), 139.73 (C9a), 142.62 (C7), 144.76 (C5a),
145.29 (C2), 153.49 (C10a). EI MS m/z: 215 (M, 100), 200
(M-CH3, 45). Anal. calcd. for: C11H9N3S C 61.37, H 4.21,
N 19.52. Found: C 61.24, H 4.21, N 19.49.
10-Allyl-1,6-diazaphenothiazine (9) (103 mg, 86 %); a dark
yellow oil 1H NMR (CDCl3) δ: 4.63 (m, 2H, NCH2), 5.27
(m, 2H, =CH2), 5.99 (m, 1H, CH), 6.76 (dd, J= 7.5 Hz, J
= 4.8 Hz, 1H, H3), 6.97 (m, 2H, H8, H9), 7.23 (dd, J= 7.5
Hz, J= 1.5 Hz, 1H, H4), 7.96 (m, 2H, H2, H7).
13C NMR
(CDCl3) δ: 47.82 (CH, CH2), 117.20 (CH, CH2=), 132.58
(CH, CH=), 115.77 (C, C4a), 118.48 (CH, C3), 121.77 (CH,
C9), 122.09 (CH, C8), 134.62 (CH, C4), 139.02 (C, C9a),
141.40 (CH, C7), 143.98 (C, C5a), 145.29 (CH, C2), 152.04
(C, C10a). EI MS m/z: 241 (M, 55), 200 (M-CH2CHCH2,
100). Anal. calcd. for: C13H11N3S C 64.70, H 4.59, N
17.41. Found: 64.67, H 4.56, N 17.32.
10-Benzyl-1,6-diazaphenothiazine (11) (95 mg, 65 %); a
dark yellow oil 1H NMR (CDCl3) δ: 5.29 (s, 2H, CH2),
6.68 (m,1H, H3), 6.88 (m, 2H, H9, H8), 7.27 (dd, J= 7.2 Hz,
J= 1.4 Hz, 1H, H4), 7.38 (m, 5H, C6H5), 7.92 (m, 2H, H2,
H7).
13C NMR (CDCl3) δ: 48.78 (CH, CH2), 116.22 (C,
C4a), 118.43 (CH, C3), 121.45 (CH, C9), 121.83 (CH, C8),
126.45 (2CH, o-CH), 126.98 (CH, p-CH), 128.82 (2CH, m-
CH), 134.46 (CH, C4), 136.60 (C, CCH2), 138.44 (C, C9a),
142.66 (CH, C7), 144.38 (C, C5a), 145.34 (CH, C2), 152.52
(C, C10a). EI MS m/z: 291 (M, 30), 200 (M-CH2C6H5, 100).
Anal. calcd. for: C17H13N3S C 70.08, H 4.50, N 14.42.
Found: C 70.04, H 4.54, N 14.30.
10-(3′-Nitro-4′-pyridinyl)-1,6-diazaphenothiazine (12)
(125 mg, 75 %); as red needles (EtOH), m.p. 167–169 °C
1H NMR (CDCl3) δ: 6.32 (d, 1H), 6.81 (m, 1H), 6.89 (m,
1H), 7.33 (d,1H, H4), 7.53 (d, 1H), 7.72 (d, 1H), 8.06 (d,
1H), 9.04 (d, 1H), 9.42 (s, 1H). 13C NMR (CDCl3) δ:
116.07 (C, C4a), 119.74 (CH, C3), 121.95 (CH, C8), 123.21
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(CH, C9), 126.36 (CH, C5′), 135.08 (CH, C4), 138.19 (C,
C9a), 141.06 (C, C4′), 144.01 (C, C5a) 144.06 (CH, C7),
144.68 (CH, C2), 146.09 (C, C3′), 146.85 (C, C2′), 149.50
(C, C10a) 156.24 (CH, C6′), 145.34 (CH, C2), 152.52 (C,
C10a). EI MS m/z: 323 (M, 60), 277 (M+1-NO2, 100), 200
(M-NO2C6H4, 10). Anal. calcd. for: C15H9N5O2S C 55.72,
H 2.81, N 21.66 Found: C 56.04, H 2.96, N 22.01.
Synthesis of 10-propargyl-1,6-diazaphenothiazines (10)
To a suspension of 10H-1,6-diazaphenothiazine (7) (100
mg, 0.5 mmol) in DMF (10 mL) potassium tert-butoxide
(80 mg, 0.72 mmol) was added. The mixture was stirred at
room temperature for 1 h. Then to the solution 80 % solu-
tion of propargyl bromide (80 mg, 0.64 mmol) in dry
toluene (0.12 mL) was added dropwise. The solution stirred
at room temperature for 24 h and poured into water (20 mL),
extracted with methylene chloride (20 mL), dried with
anhydrous Na2SO4, evaporated to the brown oil. The resi-
due was puriﬁed by column chromatography (silica gel,
CHCl3) to yield 10-propargyl-1,6-diazaphenothiazine (10)
(83 mg, 70 %); dark yellow needles (EtOH), m.p. 96–97 °C.
1H NMR: δ 2.31 (t, J= 2.4Hz, 1H), 4.69 (d, J= 2.4 Hz,
2H), 6.84 (dd, J= 7.5 Hz, J= 5.1 Hz, 1H, H3), 7.06 (dd, J
= 7.5 Hz, J= 5.1 Hz, 1H, H8), 7.31 (m, 2H, H4, H9), 8.10
(d, J= 5.5 Hz, 1H, H7), 8.3 (dd, J= 5.1 Hz, J= 1.2 Hz, 1H,
H7), 8.15 (dd, J= 5.1 Hz, J= 1.3 Hz, 1H, H2).
13C NMR
(CDCl3) δ: 35.03 (CH, NCH2), 72.50 (CH, CH2CCH),
79.10 (C, CH2CCH), 116.40 (C, C4a), 118.69 (CH, C3),
121.04 (CH, C9), 122.02 (CH, C8), 134.65 (CH, C4), 137.84
(C, C9a), 143.13 (CH, C7), 144.54 (C, C5a), 145.34 (CH,
C2), 151.87 (C, C10a). EI MS: 239 (M, 90), 200 (M-
CH2CCH, 100). Anal. calcd. for: C13H9N3S C 65.25, H
3.79, N 17.56. Found: C 65.21, H 3.74, N 17.38.
Synthesis of 10-substituted 1,6-diazaphenothiazines 13–16
To a solution of 10H-1,6-diazaphenothiazine (7) (100 mg,
0.5 mmol) in dry dioxane (10 mL) NaOH (200 mg, 5 mmol)
was added. The mixture was reﬂuxed for 1,5 h and hydro-
chloride of dialkylaminoalkyl chloride (2-diethylami-
noethyl) and hydrochloride of cycloaminoethyl chloride 1-
(2-chloroethyl)pyrrolidine, 1-(2-chloroethyl)piperidine, 2-
(2-chloroethyl)-1-methylpiperidine 1.5 mmol) was added.
The reaction mixture was reﬂuxed for 24 h. After cooling
dioxane was evaporated in vacuo and residue was dissolved
in CHCl3 (10 mL). The extracts were washed with water,
dried with anhydrous Na2SO4 and evaporated in vacuo. The
obtained product was puriﬁed by column chromatography
(aluminum oxide, CH2Cl2) to give:
10-(2′-Diethylaminoethyl)-1,6-diazaphenothiazine (13)
(110 mg, 72 %); a beige oil 1H NMR: δ 1.06 (t, J= 7.2 Hz,
6H, 2CH3), 2.65 (q, J= 7.2 Hz, 4H, 2CH2), 2.78 (t, J= 7.2
Hz, 2H, CH2), 4.08 (t, J= 7.2 Hz, 2H, CH2), 6.72 (dd, J=
7.8 Hz, J= 4.8 Hz, 1H, H3), 6.97 (dd, J= 7.8 Hz, J= 4.8
Hz, 1H, H8), 7.13 (dd, J= 7.2 Hz, J= 1.2 Hz, 1H, H4), 7.19
(dd, J= 7.2 Hz, J= 1.2 Hz, 1H, H9), 7.94 (m, 2H, H2, H7).
13C NMR (CDCl3) δ: 11.96 (2CH, 2CH3), 44.00 (CH,
NCH2), 47.69 (2C, 2CH2CH3), 48.98 (CH, NCH2), 116.30
(C, C4a), 118.07 (CH, C3), 120.66 (CH, C9), 122.00 (CH,
C8), 134.25 (CH, C4), 138.77 (C, C9a), 142.39 (CH, C7),
144.39 (C, C5a), 145.13 (CH, C2), 152.42 (C, C10a). FAB
MS m/z: 301 (M+1, 20), 228 (M+1-NC4H10, 100), 200 (M
+1-C2H4NC4H10, 25). Anal. calcd. for: C16H20N4S C 63.97;
H 6.71; N 18.65. Found: C 63.88; H 6.74; N 18.43.
10-(2′-Pyrrolidinylethyl)-1,6-diazaphenothiazine (14) (110mg,
75%); a beige oil 1H NMR (CDCl3) δ: 1.48 (m, 2H, CH2),
1.60 (m, 4H, 2CH2), 2.52 (m, 4H, 2CH2), 2.68 (t, J= 7.5Hz,
2H, CH2), 4.15 (t, J= 7.5Hz, 2H, NCH2), 6.73 (dd, J= 7.8
Hz, J= 4.8 Hz, 1H, H3), 6.96 (dd, J= 7.8Hz, J= 4.8Hz, 1H,
H8),7.12 (m, 2H, H4, H9), 7.94 (m, 2H, H2, H7).
13C NMR
(CDCl3) δ: 23.35 (2CH, 2CH2) 40.90 (CH, NCH2), 49.42 (CH,
NCH2), 53.57 (2CH, 2CH2), 115.99 (C, C4a), 118.66 (CH, C3),
120.11 (CH, C9), 122.01 (CH, C8), 135.78 (CH, C4), 137.94
(C, C9a), 143.15 (CH, C7), 144.66 (C, C5a), 145.36 (CH, C2),
152.29 (C, C10a). FAB MS m/z: 299 (M+1, 100), 202 (M+1-
C2H4NC4H8, 29). Anal. calcd. for: C16H18N4S C 64.40; H
6.08; N 18.78. Found: C 64.25; H 6.05; N 18.55.
10-(2′-Piperydinylethyl)-1,6-diazaphenothiazine (15) (112
mg, 72 %); a beige oil 1H NMR (CDCl3) δ: 1.48 (m, 2H,
CH2), 1.61 (m, 4H, 2CH2) 2.52 (m, 4H, 2CH2), 2.68 (t, J=
6.8 Hz, 2H, CH2), 4.13 (t, J= 6.8 Hz, 2H, NCH2), 6.73 (dd,
J= 7.8 Hz, J= 4.8 Hz, 1H, H3), 6.96 (dd, J= 7.8 Hz, J=
4.8 Hz, 1H, H8), 7.12 (m, 2H, H4, H9), 7.94 (m, 2H, H2,
H7).
13C NMR (CDCl3) δ: 23.86 (CH, CH2), 25.32 (2CH,
2CH2), 42.47 (CH, NCH2), 54.41 (2CH, 2CH2), 54.86 (CH,
NCH2), 116.43 (C, C4a), 118.21 (CH, C3), 120.91 (CH, C9),
122.22 (CH, C8), 134.34 (CH, C4), 138.50 (C, C9a), 142.59
(CH, C7), 144.22 (C, C5a), 145.10 (CH, C2), 152.26 (C,
C10a). FAB MS m/z: 313 (M+1, 100), 202 (M+1-
C2H4NC5H10, 20). Anal. calcd. for: C17H20N4S: C 65.35; H
6.45; N 17.93. Found: C 65.22; H 6.47; N 17.80.
10-(1′-Methyl-2′-piperydinylethyl)-1,6-diazaphenothiazine
(16) (119 mg, 74 %); a beige oil 1H NMR (CDCl3) δː
1.30–2.15 (m, 7H), 2.38 (s, 3H, NCH3), 2.94 (m, 1H, CH),
4.02 (m, 2H, NCH2), 6.73 (dd, J= 7.6 Hz, J= 5.1 Hz, 1H,
H3), 6.96 (m, 2H, H8, H4), 7.20 (m, 1H, H9), 7.94 (m, 2H,
H2, H7).
13C NMR (CDCl3) δ: 23.93 (CH, CH2), 25.11 (CH,
CH2), 28.58 (CH, CH2), 30.38 (CH, CH2), 41.00 (CH,
NCH3), 42.50 (CH, CH2), 56.79 (CH, CH), 62.34 (CH,
NCH2), 116.38 (C, C4a), 118.10 (CH, C3), 120.28 (CH, C9),
122.02 (CH, C8), 134.37 (CH, C4), 138.57 (C, C9a), 142.41
(CH, C7), 144.61 (C, C5a), 145.14 (CH, C2), 152.47 (C,
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C10a). FAB MS. 327 (M+H, 80), 313 (M+1-CH3 100).
Anal. calcd. for: C18H22N4S C 66.22; H 6.79; N 17.16.
Found: C 66.17; H 6.75; N 17.05.
Synthesis of 10-phthalimidopropyl-1,6-diazaphenothiazines
(17)
To a stirred solution of 10H-1,6-diazaphenothiazine (7)
(100 mg, 0.5 mmol) in dry toluene (20 mL) NaH (0.12 g,
5 mmol, washed out with hexane) was added. The mixture
was stirred for 30 min at room temperature, then reﬂuxed
for 1 h and a solution of N-(3-bromopropyl)phthalimide
(405 mg, 1.5 mmol) in toluene (10 mL) was added. The
mixture was reﬂuxed for 48 h. After cooling the resulted
solid was ﬁltered off, toluene was evaporated in vacuo and
the residue was puriﬁed by column chromatography (alu-
minum oxide, CHCl3) to give 10-(3′-phthalimidopropyl)-
1,6-diazaphenothiazine (17) (115 mg, 73 %), reddish nee-
dles (Et2O), m.p. 42–44 °C.
1H NMR (CDCl3) δː 2.28 (m,
2H, CH2), 3.43 (t, J= 6.1 Hz, 2H, NCH2), 3.87 (t, J= 6.0
Hz, 2H, NCH2), 6.72 (m, 2H, H3, H9), 6,88 (m, 1H, H8),
7.18 (m, 1H, H4), 7.74 (m, 2Hphthalimide), 7.79 (m, 1H, H7),
7.87 (m, 2Hphthalimide) 7.92 (m, 2H, H2).
13C NMR (CDCl3)
δ: 29.82 (CH, CH2), 31.65 (CH, NCH2), 36.74 (CH,
NCH2), 114.95 (C, C4a), 118.40 (CH, C9), 120.42 (CH, C3),
122.26 (CH, C8), 123.36 (2CH, 2CHphthalimide), 132.00 (2C,
2Cphthalimide), 134.09 (2CH, 2CHphthalimide), 135.66 (CH,
C4), 136.11 (C, C10a), 141.23 (C, C9a), 143.39 (CH, C2),
144.68 (CH, C7), 151.16 (C, C5a), 168.29 (2C, 2CO). FAB
MS m/z: 389 (M+1, 100), 201 (M+1-(CH2)3N(CO)2C6H4,
30). Anal. calcd. for C21H16N4O2S: C 64.93, H 4.15, N
14.42. Found: C 64.84, H 4.19, N 14.31.
General procedure for synthesis of 10-dialkylaminobutynyl-
1,6-diazaphenothiazines (18, 19)
A mixture of 10-propargyl-1,6-diazaphenothiazine (10)
(100 mg, 0.5 mmol), paraformaldehyde (0.5 mmol), amine
(0.7 mmol) and copper(I) chloride (catalytic amount) in
peroxide-free, dry dioxane (10 mL) was heated with con-
tinuous stirring at 70–80 °C for 3 h. After cooling water (20
mL) was add and mixture was extracted with chloroform,
dried with anhydrous Na2SO4, and evaporated in vacuo.
The dry residue was dissolved in CH2Cl2 and puriﬁed by
column chromatography (aluminum oxide, CH2Cl2) to give:
10-(4-diethylaminobut-2-ynyl)-1,6-diazaphenothiazine (18)
(130 mg, 80 %); a yellowish oil 1H NMR (CDCl3) δ: 1.03
(t, J= 7.2 Hz, 6H, 2CH3), 2.50 (q, J= 7.2 Hz, 4H, 2 NCH2),
3.42 (s, 2H, CH2), 4.70 (s, 2H, CH2), 6.79 (dd, J= 7.8 Hz,
J= 4.8 Hz, 1H, H3), 7.03 (dd, J= 7.8 Hz, J= 4.8 Hz, 1H,
H8), 7.33 (m, 2H, H4, H9), 8.03 (m, 2H, H2, H7).
13C NMR
(CDCl3) δ: 11.68 (2CH, 2CH3), 35.18 (CH, CH2), 40.65
(2CH, 2CH2), 47.45 (CH, NCH2), 79.01 (C, CH2C), 80.01
(C, CH2C), 116.47 (C, C4a), 118.68 (CH, C3), 121.07 (CH,
C9), 121.90 (CH, C8), 134.68 (CH, C4), 137.78 (C, C9a),
143.13 (CH, C7), 144.66 (C, C5a), 145.16 (CH, C2), 151.92
(C, C10a). FAB MS m/z: 325 (M+1, 15), 252 (M+1-C4H10N,
100), 201 (M+1-C8H14N, 20). Anal. calcd. for: C18H20N4S
C 66.63, H 6.21, N 17.27. Found: C 66.41, H 6.27, N 17.12.
10-[4-(4-Methylpiperazin-1-yl)but-2-ynyl]-1,6-diazaphe-
nothiazine (19) (120 mg, 69 %); a yellowish oil 1H NMR
(CDCl3) δ: 1.25 (s, 3H, NCH3), 2.69 (m, 8H, 4CH2), 3.32
(s, 2H, CH2), 4.57 (s, 2H, CH2), 6.80 (dd, J= 7.8 Hz, J=
4.8 Hz, 1H, H3), 7.09 (dd, J= 7.8 Hz, J= 4.8 Hz, 1H, H8),
7.33 (m, 2H, H4, H9), 8.03 (m, 2H, H2, H7).
13C NMR
(CDCl3) δ: 23.83 (2CH, 2CH2), 25.75 (2CH, 2CH2), 35.17
(CH, CH2), 47.98 (CH, NCH3), 53.27 (CH, CH2), 79.80 (C,
CH2C), 80.10 (C, CH2C), 116.26 (C, C4a), 118.51 (CH, C3),
121.33 (CH, C9), 121.86 (CH, C8), 134.63 (CH, C4), 137.90
(C, C9a), 142.95 (CH, C7), 144.50 (C, C5a), 145.22 (C2),
151.98 (C10a). FAB MS m/z: 351 (M+1, 100), 201 (M+1-
C9H15N2, 40). Anal. calcd. for: C19H21N5S C 64.93, H
6.02, N 19.93. Found: C 64.77, H 5.94 N 19.79.
Cytotoxic and antiproliferative effects in vitro
Cell culture
Compounds were evaluated for their anticancer activity
using three cultured cell lines: SNB-19 (human glio-
blastoma, DSMZ - German Collection of Microorganisms
and Cell Cultures, Braunschweig, Germany), C-32 (human
amelanotic melanoma, ATCC - American Type Culture
Collection, Manassas, VA, USA), MCF-7 (human breast
cancer, ATCC, Manassas, VA, USA) and HFF-1 (human
ﬁbroblast cell line, ATCC, Manassas, VA, USA). The cul-
tured cells were kept at 37 °C and 5% CO2. The cells were
seeded (1 × 104 cells/well/100 μL Dulbecco's modiﬁed
Eagle's medium supplemented with 10% FCS and strepto-
mycin and penicillin) using 96-well plates (Corning).
Cell proliferation and viability
In recent years tetrazolium salts have been described to be
used for the measurement of cell proliferation and viability.
The tetrazolium salts are cleaved to formazan by cellular
enzymes. An expansion in the number of viable cells results
in an increase in the overall activity of mitochondrial
dehydrogenases in the sample. This augmentation in enzyme
activity leads to an increase in the amount of formazan dye
formed, which directly correlates to the number of metabo-
lically active cells in the culture. The formazan dye produced
by metabolically active cells is quantiﬁed by a scanning
enzyme-linked immunosorbent assay reader by measuring
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the absorbance of the dye solution at appropriate wave-
lengths (λ= 420–480 nm with a reference wavelength λ=
600 nm).
WST-1 assay
The WST-1 assay (Roche Diagnostics, Mannheim, Ger-
many) was used to evaluate the effect of compounds on the
number of cells in cultures, which as the cytotoxic effect of
the tested compounds and their inﬂuence on the prolifera-
tion of cells. After exposure to tested compounds (at con-
centrations between 0 and 100 μg/mL) for 72 h, cells were
incubated with WST-1 (10 μL) for 1 h, and the absorbance
of the samples against a background control was read at
450 nm with a reference wavelength λ= 600 nm using a
microplate reader UVM340 (Biogenet). Results are
expressed as means of at least two independent experiments
performed in triplicate.
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